Shanghai Haohai Valuation Multiples

Shanghai Haohai Overview

About Shanghai Haohai

Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.

Founded

2007

HQ

Employees

2.2K

Website

3healthcare.com

Sectors

Medical DevicesBioTech

Financials (LTM)

Revenue: $363M

EBITDA: $72M

EV

$883M

Valuation Multiples

Multiples.vc

Start free trial

Shanghai Haohai Financials

Shanghai Haohai reported last 12-month revenue of $363M and EBITDA of $72M.

In the same LTM period, Shanghai Haohai generated $255M in gross profit, $72M in EBITDA, and $43M in net income.

Shanghai Haohai P&L

In the most recent fiscal year, Shanghai Haohai reported revenue of $393M and EBITDA of $101M.

Shanghai Haohai expects next 12-month revenue of XXX and NTM EBITDA of XXX

Shanghai Haohai Stock Performance

Shanghai Haohai has current market cap of $1B, and enterprise value of $883M.

Shanghai Haohai's stock price is $5.29.

Shanghai Haohai Valuation Multiples

Shanghai Haohai trades at 2.4x EV/Revenue multiple, and 12.2x EV/EBITDA.

Shanghai Haohai Financial Valuation Multiples

As of April 21, 2026, Shanghai Haohai has market cap of $1B and EV of $883M.

Equity research analysts estimate Shanghai Haohai's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Shanghai Haohai has a P/E ratio of 27.8x.

Shanghai Haohai Margins & Growth Rates

Shanghai Haohai's revenue in the last 12 month grew by 8%.

Shanghai Haohai's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Shanghai Haohai's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Shanghai Haohai's rule of X is 46% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Shanghai Haohai Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Shanghai Haohai M&A Activity

Shanghai Haohai acquired XXX companies to date.

Last acquisition by Shanghai Haohai was on XXXXXXXX, XXXXX. Shanghai Haohai acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Shanghai Haohai Investment Activity

Shanghai Haohai invested in XXX companies to date.

Shanghai Haohai made its latest investment on XXXXXXXX, XXXXX. Shanghai Haohai invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).